Skip to main content

Table 2 Factors associated with benefit from neoadjuvant chemotherapy in non-small-cell lung cancer

From: The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Factors All trials Stage 1 to 3 (mixed-stage trials) Stage 3  
  B (95% CI)a P value B (95% CI) P value B (95% CI) P value
Disease characteristics       
Histology (squamous cell fraction) −0.00 (−0.01 to 0.00) 0.600 0.00 (−0.01 to 0.01) 0.536 −0.00 (−0.01 to 0.00) 0.261
Stage (1 to 3 vs 3 only) −0.06 (−0.17 to 0.05) 0.256 NRb NRb NRb NRb
Treatment characteristics       
Platinum type (carboplatin vs cisplatin based) −0.07 (−0.15 to 0.04) 0.205 −0.05 (−0.18 to 0.09) 0.411 NRc NRc
Generation of drugs (older vs third-generation agent protocol) −0.03 (−0.09 to 0.14) 0.639 −0.04 (−0.19 to 0.11) 0.572 −0.09 (−0.16 to 0.34) 0.373
Number of drugs (2 vs 2 to 3 vs 3 drugs) −0.01 (−0.09 to 0.06) 0.695 −0.03 (−0.04 to 0.11) 0.303 −0.18 (−0.27 to −0.08) 0.006
Number of chemotherapy cycles 0.00 (−0.09 to 0.10) 0.955 −0.04 (−0.19 to 0.11) 0.572 −0.01 (−0.23 to 0.21) 0.871
Trial characteristics       
Trial sized 0.00 (−0.01 to 0.01) 0.569 −0.00 (−0.02 to 0.01) 0.530 0.01 (−0.02 to 0.03) 0.514
Publication year 0.01 (−0.01 to 0.02) 0.605 −0.00 (−0.02 to 0.01) 0.535 0.03 (−0.03 to 0.09) 0.215
Origin of study (European vs Asian vs US) −0.01 (−0.10 to 0.08) 0.885 0.03 (−0.09 to 0.15) 0.566 0.03 (−0.03 to 0.34) 0.841
Trial quality scoree 0.03 (−0.04 to 0.09) 0.373 0.04 (−0.03 to 0.10) 0.186 0.12 (−0.16 to 0.40) 0.300
  1. aRegression coefficient and 95% confidence interval.
  2. bNot relevant.
  3. cAnalysis not performed due to insufficient number of trials in that subgroup.
  4. dSquare root transformation. For analyses for trial size, analyses have not been weighed for trial size.
  5. eOver a scale from 0 to 3, depending on randomization method (details given vs not given), stratification criteria (reported vs not reported) and trial type (reported in full text or abstract).